MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
and sales of...
$25,085K
Proceeds from sale of
common stock and...
$14,843K
Proceeds from issuance of
common stock through...
$1,471K
Proceeds from sale of
property and equipment
$948K
Proceeds from employee
stock awards
$35K
Net cash provided by
investing activities
$18,148K
Net cash provided by
financing activities
$16,098K
Canceled cashflow
$7,885K
Canceled cashflow
$251K
Decrease in cash, cash
equivalents and restricted...
-$16,694K
Canceled cashflow
$34,246K
Net income (loss)
$32,688K
Inventories
-$10,655K
Stock-based compensation
expense
$9,752K
Other current assets
-$6,170K
Non-cash operating lease
expense
$4,996K
Loss on impairment of
lease right-of-use...
$4,130K
Accretion of liability
related to sale of future...
$3,578K
Depreciation and
amortization expense
$2,116K
Amortization (accretion) of
investment premiums...
-$259K
Accounts receivable
-$229K
Other non-cash items,
net
$94K
Other assets
-$15K
Other long-term
liabilities
$1K
Purchases of short-term
investments
$7,885K
Principal payments on
finance lease...
$250K
Other financing
activities, net
-$1K
Net cash used in
operating activities
-$50,940K
Canceled cashflow
$74,683K
Deferred revenue
-$94,376K
Accrued research and
development expenses
-$7,902K
Operating lease
liabilities
-$5,453K
Accrued compensation
-$5,318K
Other current
liabilities
-$4,516K
Accounts payable
-$4,240K
Gain on
derecognition of lease...
$3,818K
Back
Back
Cash Flow
source: myfinsight.com
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)